Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
Juwan Park1, Michael S Lee2, Andrew R Harrison31Department of Ophthalmology, The Catholic University of Korea, Seoul, Korea; 2Department of Ophthalmology, Neurology and Neurosurgery, 3Department of Ophthalmology and Otolaryngology, University of Minnesota, MN, USAAbstract: Even though conventional b...
Guardado en:
Autores principales: | Park J, Lee MS, Harrison AR |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dc46dfaebe1046dda2310de72c92e40d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins
por: Jimenez-Shahed J
Publicado: (2011) -
Azithromycin in DuraSite® for the treatment of blepharitis
por: Jodi Luchs
Publicado: (2010) -
Botulinum toxin injections for blepharospasm prior to ocular surgeries
por: Kaydu E, et al.
Publicado: (2012) -
Comparison of ultra-widefield fluorescein angiography with the Heidelberg Spectralis® noncontact ultra-widefield module versus the Optos® Optomap®
por: Witmer MT, et al.
Publicado: (2013) -
Comparison of outcomes of conventional WaveLight® Allegretto Wave® and Technolas® excimer lasers in myopic laser in situ keratomileusis
por: Han DC, et al.
Publicado: (2012)